The concept of anti-aging is gaining momentum in the market as the effects of aging such as skin elasticity loss and collagen loss are observed in the Indian population. As a result of this, the India anti-aging drugs market is expected to grow during the forecast period. The market is segmented by type and by treatment.
The increasing rate of neurological disorders in India has resulted in the India neurology devices market to grow from $230 Mn in 2022 to $521 Mn in 2030 with a CAGR of 10.8% for the year 2022-2030. Stroke, brain injuries, and epilepsy are the most prevalent neurological disorders in India.
Glaucoma and dry eye are the most common eye disorders affecting the population globally, hence the demand for Over The Counter (OTC) drugs is on the rise thereby leading to the growth of the Global OTC ophthalmic drugs market. The market is segmented by indication and by dosage form.
Global Patient Support Programs (PSP) market is projected to grow during the forecast period as a result of more pharma companies investing in these programs and due to the rise in the demand for personalized medicine. Connect 360 by AstraZeneca and Assist 360 by Amgen are some of the top pharma-sponsored PSP programs.
The market size of Canada OTC market was valued at $13.62 Bn in 2022 to $23.58 Bn in 2030 with a CAGR of 7.1% for the year 2022-2030. The Canada OTC market is segmented by drug type and by distribution channel. Johnson and Johnson and Pfizer are some of the key players in the market.
The Brazil OTC pharmaceuticals market is projected to grow from $4.25 Bn in 2022 to $7.93 Bn in 2030 with a CAGR of 8.1% for the year 2022-2030. Greater accessibility of the otc drugs and switching of prescription drugs to otc drugs are the major market drivers of Brazil otc pharmaceuticals market.
Brazil ophthalmology therapeutics market is projected to grow owing to the increasing demand for high-innovation combination therapies for the treatment of glaucoma and other eye-related disorders. The market is segmented by indication and by end users.
The Australia physiotherapy market is expected to witness growth from $638 Mn in 2022 to $1,126 Mn in 2030 with a CAGR of 7.35% for the year 2022-2030. Arthritis, osteoporosis and back pain are the major conditions that require physiotherapy. The market is segmented by treatments and conditions.
The APAC Autoimmune Hemolytic Anemia (AIHA) market is expected to grow as a result of the increased prevalence of AIHA in the APAC region. The market is segmented by disease type, therapy type, drugs, and by route of administration. AstraZeneca and Roche are some of the key players in the APAC AIHA market.
China Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market is growing due to the increased cases of PNH cases in China. Although being a rare disease, its prevalence in China and the increased adoption of novel therapeutics to treat PNH are the major market drivers of the China PNH therapeutics market.
Patient Support Programs (PSP) in Australia provide patients with significant value through the accessibility of information and support during and after the course of their treatment, therefore, leading to the growth of Australia patient support programs. Pharmaceutical companies sponsored PSPs are designed to aid compliance and lifestyle choices.
The demand for physiotherapy services keeps increasing due to the rising geriatric population and musculoskeletal disorders and injuries thereby providing more opportunities for the Singapore physiotherapy market to grow. The physiotherapy market is segmented by treatment and conditions.